EHA 2025 | Comparative efficacy of GIMEMA LAL1913 chemotherapy protocol versus standard arm of E1910 in ALL
Alfonso Piciocchi, MS, GIMEMA Foundation, Rome, Italy, discusses a matching-adjusted indirect comparison (MAIC) analysis of the comparative efficacy of the GIMEMA LAL1913 (NCT02067143) chemotherapy protocol versus the standard arm of the E1910 trial (NCT02003222) in measurable residual disease (MRD)-negative, Ph-negative acute lymphoblastic leukemia (ALL). Mr Piciocchi reports similar overall survival and disease-free survival rates, supporting the clinical equivalence of these protocols. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The matching adjusted indirect comparison analysis demonstrated that the GIMEMA LAL1913 chemotherapy regimen achieved outcomes comparable to the standard chemotherapy arm of the E1910 trial in MRD negative PH-b negative lineage acute lymphoblastic leukemia patients. After adjusting for key baseline characteristics using individual patients’ data from the GIMEMA trial LAL1913, they adjusted three-year overall survival and three-year disease-free survival were 6-8% and roughly 6% respectively, closely matching the rate reported in the E1910 standard arm...
The matching adjusted indirect comparison analysis demonstrated that the GIMEMA LAL1913 chemotherapy regimen achieved outcomes comparable to the standard chemotherapy arm of the E1910 trial in MRD negative PH-b negative lineage acute lymphoblastic leukemia patients. After adjusting for key baseline characteristics using individual patients’ data from the GIMEMA trial LAL1913, they adjusted three-year overall survival and three-year disease-free survival were 6-8% and roughly 6% respectively, closely matching the rate reported in the E1910 standard arm. These results support the clinical equivalence of the Italian protocol and indirectly reinforce the added value of blinatumomab which improved the outcomes when added to the standard therapy in the E1910 trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
